Vincerx Pharma, Inc.

Vincerx Pharma, Inc. (Nasdaq: VNRX) is a clinical-stage biopharmaceutical company focused on hematologic malignancies that completed its business combination with LifeSci Acquisition Corp, a blank-check company sponsored by LifeSci Capital LLC, in December 2020. The SPAC vehicle, which traded under the ticker LSAC, completed its IPO in 2020 and targeted the life sciences sector. Vincerx has been developing novel cancer therapies with a focus on blood cancers and filed the referenced Form 8-K with the SEC on February 6, 2025, as part of its ongoing public-company reporting obligations. The company operates in the biopharmaceutical and oncology space and remains listed on the Nasdaq Capital Market. Visit SpacDesk and sign up for full data, filings history, and SPAC deal analytics on Vincerx and hundreds of other de-SPAC companies.